Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchases of marketable securities | (78,438) | (118,557) |
| Maturities of marketable securities | 59,220 | 156,201 |
| Purchases of property and equipment | — | (327) |
| Net cash provided by (used in) investing activities | (19,218) | 37,317 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | 13,670 | 2,042 |
| Employee taxes paid related to net share settlement of equity awards | (4,555) | (3,341) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's capex?
- Supernus Pharmaceuticals (SUPN) reported capex of $0 in Q1 2026.
- How has Supernus Pharmaceuticals's capex changed year-over-year?
- Supernus Pharmaceuticals's capex decreased by 100.0% year-over-year, from $327K to $0.
- What is the long-term trend for Supernus Pharmaceuticals's capex?
- Over 2 years (2023 to 2025), Supernus Pharmaceuticals's capex has grown at a 51.0% compound annual growth rate (CAGR), from $587K to $1.34M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Supernus Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude